miR-193b与子宫内膜癌临床病理表现的关系及其对化疗敏感性的影响研究  

Relationship between miR-193b and clinicopathological features of endometrial carcinoma and its effect on chemosensitivity

作　　者：陈晨晨[1] 彭存旭[1] 吕艳华[1] CHEN Chenchen;PENG Cunxu;LYU Yanhua(Department of Gynaecology,Affiliated Hospital of Jining Medical College,Jining,Shandong 272000,China)

机构地区：[1]济宁医学院附属医院妇科,山东济宁272000

出　　处：《中国优生与遗传杂志》2022年第3期446-451,共6页Chinese Journal of Birth Health & Heredity

基　　金：山东省中医药科技发展计划项目(2019-0482)。

摘　　要：目的 研究miR-193b在子宫内膜癌组织中的表达,以及其与临床病理参数的关系,并探讨其对子宫内膜癌Ishikawa细胞紫杉醇化疗敏感性的影响。方法 检测68例子宫内膜癌组织中miR-193b的表达水平,以60例正常子宫内膜组织作为对照组,探讨其表达与子宫内膜癌临床病理资料的关系。设计miR-193bsiRNA及miR-193b利用脂质体2000转染入细胞内,并通过real-timePCR检测其转染效率,利用MTT法体外划痕实验验证miR-193b联合紫杉醇对肿瘤细胞的杀伤效力,利用生物信息学、real-time PCR和Western blot方法验证miR-193b是否调节子宫内膜癌细胞Mcl-1的表达。构建Mcl-1真核表达载体,MTT法和流式细胞术检测Mcl-1表达载体转染对miR-193b联合紫杉醇治疗子宫内膜癌疗效的影响。结果 与正常子宫内膜组织相比较,miR-193b在子宫内膜癌组织中表达下调(P<0.05)。不同临床肿瘤分期、病理分级、肌层浸润深度子宫内膜癌患者miR-193b表达水平分别比较,差异均具有统计学意义(P<0.05),而不同年龄、淋巴转移、脉管侵袭、远处转移的子宫内膜癌组织中miR-193b的表达水平分别比较,差异均无统计学意义(P>0.05)。miR-193b联合紫杉醇治疗组对子宫内膜癌细胞的杀伤效力显著高于紫杉醇单治疗组。miR-193b转染后,子宫内膜癌细胞Mcl-1的mRNA及蛋白表达水平均下降。miR-193b联合紫杉醇在Mcl-1表达载体转染后对子宫内膜癌细胞的杀伤活性显著低于未转染Mcl-1表达载体的miR-193b联合紫杉醇治疗组。结论 miR-193b的表达与子宫内膜癌的发生发展、转移和侵袭能力密切相关,且miR-193b可通过靶向于Mcl-1增强紫杉醇对子宫内膜癌细胞的杀伤效力。Objective To investigate the expression of miR-193b in endometrial carcinoma and its relationship with clinicopathological parameters,and to explore its effect on chemosensitivity of endometrial cancer Ishikawa cells.Methods The expression levels of miR-193b in 68 cases of endometrial carcinoma were detected.60 cases of normal endometrium were used as control group to investigate the relationship between the expression and clinicopathological data of endometrial cancer.The miR-193b siRNA and miR-193b were transfected into the cells by liposome 2000,and the transfection efficiency was detected by real-time PCR.The in vitro scratching experiment of MTT method was used to verify the killing of tumor cells by miR-193b combined with paclitaxel.Efficacy,using bioinformatics,real-time PCR and Western blot methods to verify whether miR-193b regulates the expression of Mcl-1 in endometrial cancer cells.Mcl-1 eukaryotic expression vector was constructed,MTT assay and flow cytometry were used to detect the effect of Mcl-1 expression vector transfection on the efficacy of miR-193b combined with paclitaxel in the treatment of endometrial cancer.Results Compared with normal endometrial tissue,miR-193b was down-regulated in endometrial carcinoma tissues(P<0.05).The expression levels of miR-193b in different clinical tumor staging,pathological grade,and myometrial invasion of endometrial cancer were statistically significant(P<0.05),but the expression levels of miR-193b in metastatic endometrial carcinoma tissues with different ages,lymphatic metastasis,vascular invasion and distant metastasis were compared,and the differences were not statistically significant(P>0.05).The killing efficacy of miR-193b combined with paclitaxel in the endometrial cancer cells was significantly higher than that in the paclitaxel monotherapy group.After miR-193b transfection,the mRNA and protein expression levels of Mcl-1in endometrial cancer cells decreased.The killing activity of miR-193b combined with paclitaxel on the endometrial cancer cells af

关 键 词：miR-193b 子宫内膜癌 病理表现 紫杉醇 MCL-1 

分 类 号：R737.33[医药卫生—肿瘤]